These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18516354)

  • 41. The undertreatment of LDL-cholesterol: addressing the challenge.
    Pearson TA
    Int J Cardiol; 2000 Jun; 74 Suppl 1():S23-8. PubMed ID: 10856770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark.
    Graversen L; Christensen B; Borch-Johnsen K; Lauritzen T; Sandbaek A
    Scand J Prim Health Care; 2010 Mar; 28(1):47-54. PubMed ID: 19929180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
    Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
    BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study).
    Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S
    J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ineffectiveness of lipid-lowering therapy in primary care.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Travier N; Yin D; Alemao E; de Pouvourville G
    Br J Clin Pharmacol; 2005 Apr; 59(4):456-63. PubMed ID: 15801941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study.
    da Silva PM; Aguiar C; Morais J;
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):559-569. PubMed ID: 31706732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.
    Itoh H; Komuro I; Takeuchi M; Akasaka T; Daida H; Egashira Y; Fujita H; Higaki J; Hirata KI; Ishibashi S; Isshiki T; Ito S; Kashiwagi A; Kato S; Kitagawa K; Kitakaze M; Kitazono T; Kurabayashi M; Miyauchi K; Murakami T; Murohara T; Node K; Ogawa S; Saito Y; Seino Y; Shigeeda T; Shindo S; Sugawara M; Sugiyama S; Terauchi Y; Tsutsui H; Ueshima K; Utsunomiya K; Yamagishi M; Yamazaki T; Yo S; Yokote K; Yoshida K; Yoshimura M; Yoshimura N; Nakao K; Nagai R;
    Diabetes Obes Metab; 2019 Apr; 21(4):791-800. PubMed ID: 30393955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey.
    Sukonthasarn A; Homsanit M; Prommete B; Chotinaiwattarakul C; Piamsomboon C; Likittanasombat K
    J Med Assoc Thai; 2011 Dec; 94(12):1424-34. PubMed ID: 22295727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).
    Devroey D; Radermecker RP; Van der Schueren BJ; Torbeyns B; Jaken RJ
    Int J Clin Pract; 2014 Feb; 68(2):180-7. PubMed ID: 24308644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy.
    Presta V; Figliuzzi I; Miceli F; Coluccia R; Fogacci F; Cicero AFG; Ferrucci A; Borghi C; Volpe M; Tocci G;
    Atherosclerosis; 2019 Jun; 285():40-48. PubMed ID: 31003091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
    Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
    Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes.
    Hero C; Svensson AM; Gidlund P; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K
    Diabet Med; 2016 Mar; 33(3):316-23. PubMed ID: 26498834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Soran H; Adam S; Durrington PN
    Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study.
    Leśniak W; Bała MM; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jankowski M; Sieradzki J; Banasiak W;
    Cardiol J; 2015; 22(2):150-9. PubMed ID: 25299503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study.
    Danese MD; Sidelnikov E; Kutikova L
    Curr Med Res Opin; 2018 Aug; 34(8):1441-1447. PubMed ID: 29627994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.